Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Intravenous Iron in Patients With Anemia of Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00204256
Recruitment Status : Unknown
Verified September 2005 by University Hospital Muenster.
Recruitment status was:  Active, not recruiting
First Posted : September 20, 2005
Last Update Posted : September 20, 2005
Information provided by:
University Hospital Muenster

Brief Summary:
The objective of this study is the evaluation of the efficacy and safety of intravenous iron sucrose in anemic patients with chronic kidney disease not on renal replacement therapy.

Condition or disease Intervention/treatment Phase
Kidney Failure, Chronic Drug: Iron sucrose Phase 4

Detailed Description:
This is a randomized, open label, phase IV study in anemic predialysis patients (Hb between 8 and 11.5 g/dl) who require iron supplementation. The duration of the study for each patient will be approximately 6 months. Patients will be randomized to one of two treatment arms and admitted to the anemia correction phase (days 1-43). Treatment will be intravenous iron sucrose alone versus iron sucrose plus rhEPO. The main treatment evaluation will at the end of the correction phase: The primary end-point will be the change of hemoglobin during correction phase. Secondary end-points will be the change of ferritin and transferrin saturation from baseline to day 43. Safety assessments will include recording of adverse events, vital signs, physical examinations and clinical laboratory tests. Incidence and severity of adverse events will be compared between the two different treatment arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease
Study Start Date : March 2004
Study Completion Date : March 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Change in hemoglobin from baseline to day 43

Secondary Outcome Measures :
  1. Change in ferritin and transferrin saturation from baseline to day 43; incidence and severity of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Chronic kidney disease Anemia (Hb 8 - 11.5 g/dl) Age above 18 years Signed informed consent

Exclusion Criteria:

Rapid progression of kidney disease Need for dialysis Uncontrolled hypertension

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00204256

Layout table for location information
University Hospital Muenster
Muenster, Westphalia, Germany, 48149
Sponsors and Collaborators
University Hospital Muenster
Layout table for investigator information
Principal Investigator: Roland M Schaefer, MD University Hospital Muenster

Layout table for additonal information Identifier: NCT00204256    
Other Study ID Numbers: Ven-PD-03
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: September 20, 2005
Last Verified: September 2005
Keywords provided by University Hospital Muenster:
chronic kidney disease
intravenous iron
recombinant human erythropoetin
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Failure, Chronic
Urologic Diseases
Ferric Oxide, Saccharated
Trace Elements
Growth Substances
Physiological Effects of Drugs